Naiyer A. Rizvi
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers 134
- Lung Cancer Research Studies 59
- Colorectal Cancer Treatments and Studies 40
- CAR-T cell therapy research 26
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations 140
- Lung Cancer Diagnosis and Treatment 28
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics 38
- Immunology top 0.5%
- Immunotherapy and Immune Responses 23
- Molecular Biology top 2%
- Co-authors
- Mark G. KrisVincent A. MillerScott AntoniaMatthew D. HellmannWilliam PaoGregory J. RielyScott GettingerLaura Q.M. Chow
- Partner nations
- United StatesCanadaFrance
In The Last Decade
Naiyer A. Rizvi
267 papers receiving 14.7k citations
Hit Papers
Peers
Comparison fields: 5 of 136
- Oncology 11.0k
- Pulmonary and Respiratory Medicine 7.7k
- Cancer Research 2.2k
- Immunology 3.0k
- Molecular Biology 3.5k
Countries citing papers authored by Naiyer A. Rizvi
This map shows the geographic impact of Naiyer A. Rizvi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naiyer A. Rizvi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naiyer A. Rizvi more than expected).
Fields of papers citing papers by Naiyer A. Rizvi
This network shows the impact of papers produced by Naiyer A. Rizvi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naiyer A. Rizvi. The network helps show where Naiyer A. Rizvi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Naiyer A. Rizvi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 4 | |
| 2 | 2023 | 7 | |
| 3 | 2023 | 24 | |
| 4 | 2023 | 3 | |
| 5 | 2022 | 37 | |
| 6 | 2022 | 13 | |
| 7 | 2021 | 38 | |
| 8 | 2020 | 63 | |
| 9 | 2020 | 86 | |
| 10 | 2020 | 40 | |
| 11 | 2018 | 38 | |
| 12 | Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapybreakdown → | 2017 | 738 |
| 13 | 2015 | 202 | |
| 14 | 2015 | 7 | |
| 15 | 2013 | 74 | |
| 16 | 2012 | 122 | |
| 17 | 2012 | 132 | |
| 18 | 2010 | 82 | |
| 19 | 2009 | 194 | |
| 20 | A phase II study of XL647 in patients with non-small cell lung cancer (NSCLC) enriched for presence of EGFR mutations | 2007 | 2 |
About Naiyer A. Rizvi
Naiyer A. Rizvi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 275 papers that have together received 15.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (140 papers), Cancer Immunotherapy and Biomarkers (134 papers), Lung Cancer Research Studies (59 papers), Colorectal Cancer Treatments and Studies (40 papers), Cancer Genomics and Diagnostics (38 papers), Lung Cancer Diagnosis and Treatment (28 papers), CAR-T cell therapy research (26 papers) and Immunotherapy and Immune Responses (23 papers). The work is most often cited by research in Oncology (11.0k citations), Pulmonary and Respiratory Medicine (7.7k citations) and Cancer Research (2.2k citations). Naiyer A. Rizvi has collaborated with scholars based in United States, Canada and France. Frequent co-authors include Mark G. Kris, Vincent A. Miller, Scott Antonia, Matthew D. Hellmann, William Pao, Gregory J. Riely, Scott Gettinger, Laura Q.M. Chow, Christopher G. Azzoli and Hossein Borghaei. Their work appears in journals such as Nature, Science and Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.